D
Dana E. Rollison
Researcher at University of South Florida
Publications - 147
Citations - 5956
Dana E. Rollison is an academic researcher from University of South Florida. The author has contributed to research in topics: Cancer & Population. The author has an hindex of 38, co-authored 134 publications receiving 5166 citations. Previous affiliations of Dana E. Rollison include Johns Hopkins University & Medical University of Graz.
Papers
More filters
Journal ArticleDOI
Epidemiology of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders in the United States, 2001-2004, Using Data From the NAACCR and SEER Programs
Dana E. Rollison,Nadia Howlader,Martyn T. Smith,Sara S. Strom,William D. Merritt,Lynn A. G. Ries,Brenda K. Edwards,Alan F. List +7 more
TL;DR: MDS incidence rates significantly increased with calendar year in 2001 through 2004, and only 4% of patients were reported to registries by physicians' offices, suggesting that MDS disease burden in the United States may be underestimated.
Journal ArticleDOI
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study.
Anna R. Giuliano,Ji-Hyun Lee,William J. Fulp,Luisa L. Villa,Eduardo Lazcano,Mary R. Papenfuss,Martha Abrahamsen,Jorge Salmerón,Gabriella M. Anic,Dana E. Rollison,Danelle Smith +10 more
TL;DR: The data from this study are useful for the development of realistic cost-effectiveness models for male HPV vaccination internationally.
Journal ArticleDOI
Circulating sex hormones and breast cancer risk factors in postmenopausal women: Reanalysis of 13 studies
Timothy J. Key,P N Appleby,Gillian K Reeves,Andrew W. Roddam,Andrew W. Roddam,Kathy J. Helzlsouer,Kathy J. Helzlsouer,Anthony J. Alberg,Anthony J. Alberg,Dana E. Rollison,Joanne F. Dorgan,Louise A. Brinton,Kim Overvad,Rudolf Kaaks,Antonia Trichopoulou,Françoise Clavel-Chapelon,Salvatore Panico,Eric J. Duell,Petra H.M. Peeters,Petra H.M. Peeters,S. Rinaldi,S. Rinaldi,Ian S. Fentiman,Mitch Dowsett,Jonas Manjer,Per Lenner,Göran Hallmans,Laura Baglietto,Dallas R. English,Graham G. Giles,John L. Hopper,Gianluca Severi,Howard A. Morris,Susan E. Hankinson,Shelley S. Tworoger,Karen L. Koenig,Anne Zeleniuch-Jacquotte,Alan A. Arslan,Paolo Toniolo,Roy E. Shore,Vittorio Krogh,Andrea Micheli,Franco Berrino,Elizabeth Barrett-Connor,Gail A. Laughlin,Michinori Kabuto,Suminori Akiba,Richard G. Stevens,Kazuo Neriishi,Charles E. Land,J. A. Cauley,Li Yung Lui,Steven R. Cummings,Marc J. Gunter,T E Rohan,Howard D. Strickler +55 more
TL;DR: Sex hormone concentrations were strongly associated with several established or suspected risk factors for breast cancer, and may mediate the effects of these factors on breast cancer risk.
Journal ArticleDOI
Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies.
Endogenous Hormones,Timothy J. Key,Paul N. Appleby,G Reeves,Ruth C. Travis,Anthony J. Alberg,Aurelio Barricarte,Franco Berrino,V. Krogh,Sabina Sieri,Louise A. Brinton,Joanne F. Dorgan,Laure Dossus,Mitch Dowsett,A H Eliassen,Renée T. Fortner,Susan E. Hankinson,Kathy J. Helzlsouer,J Hoff man-Bolton,George W. Comstock,Rudolph Kaaks,L L Kahle,Paola Muti,Kim Overvad,P.H.M. Peeters,Elio Riboli,S. Rinaldi,Dana E. Rollison,Frank Z. Stanczyk,D. Trichopoulos,Shelley S. Tworoger,Paolo Vineis +31 more
TL;DR: Circulating oestrogens and androgens are positively associated with the risk for breast cancer in premenopausal women, and cross-sectional analyses in control women showed several associations of sex hormones with breast cancer risk factors.
Journal ArticleDOI
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
Nancy K. Gillis,Markus Ball,Qing Zhang,Zhenjun Ma,YuLong Zhao,Sean J. Yoder,Maria E. Balasis,Tania Mesa,David A. Sallman,Jeffrey E. Lancet,Rami S. Komrokji,Alan F. List,Howard L. McLeod,Melissa Alsina,Rachid Baz,Kenneth H. Shain,Dana E. Rollison,Eric Padron +17 more
TL;DR: The prevalence of CHIP in all patients was higher than has been reported in elderly individuals without cancer and the primary exposure was CHIP, suggesting that mutation-specific differences might exist in therapy-related myeloid neoplasm risk.